Can your own immune cells beat advanced cancer?

NCT ID NCT07766317

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial tests a personalized therapy called GT201, made from a patient's own tumor-infiltrating lymphocytes (TILs). The goal is to see if these immune cells, grown in the lab and infused back into the patient, can shrink or eliminate advanced solid tumors. The study includes adults aged 18-70 with advanced solid tumors who have exhausted standard treatments. Participants receive a lymphodepleting regimen, the GT201 infusion, and IL-2, with some also receiving a PD-1 inhibitor. The trial aims to assess safety, tolerability, and anti-tumor activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GT201, a personalized cell therapy made from a patient's own tumor-infiltrating lymphocytes (TILs), given with IL-2 and possibly a PD-1 inhibitor.
What this could lead to
If successful, this could offer a new treatment option for people with advanced solid tumors who have run out of standard therapies, potentially leading to durable remissions.
What could go wrong
This is an early-phase trial, so safety and effectiveness are not yet established. The therapy involves intensive chemotherapy and IL-2, which can cause severe side effects. It may not work for all tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.